- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | Shionogi H1 Earnings Up 44%, Raises FY26 Outlook | 357 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF), a Japanese drug manufacturing company, reported a 44 percent rise in profit for the first half of fiscal 2026 on higher revenues that grew 64.5... ► Artikel lesen | |
| 29.10. | Shionogi & Co., Ltd. Bottom Line Advances In H1 | 307 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) revealed a profit for its first half that Increased, from the same period last yearThe company's bottom line came in at JPY119.546 billion, or... ► Artikel lesen | |
| 28.10. | Shionogi sichert sich mit Technologie von D-Wave Quantencomputing-Preis der NEDO über ¥40 Millionen | 46 | Investing.com Deutsch | ||
| 28.10. | Wirkstoffforschung mit Quantencomputing: Shionogi gewinnt Auszeichnung über 40 Millionen Yen | 4 | Investing.com Deutsch | ||
| 09.10. | Fierce Pharma Asia-Novartis' $7.8B mRNA deal; Shionogi's $2B buy; ArriVent's phase 3 flop | 9 | FiercePharma | ||
| 07.10. | Shionogi to Acquire IntraBio, Adding Aqneursa to Rare Disease Portfolio | 3 | Contract Pharma | ||
| 06.10. | Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout | 3 | Pharmaceutical Technology | ||
| 05.10. | Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition | 3 | MedCity News | ||
| SHIONOGI & CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 05.10. | Shionogi pays $2B to acquire a rare disease startup | 3 | BioPharma Dive | ||
| 05.10. | Shionogi agrees $2bn deal for IntraBio and its rare-neurology drug AQNEURSA | 3 | Tokyo Brief | ||
| 05.10. | Shionogi's diversification continues with $2bn IntraBio buy | 3 | pharmaphorum | ||
| 25.09. | Shionogi Amends Annual Report, Cuts Disclosed Director Pay Total | 3 | Tokyo Brief | ||
| 16.09. | Shionogi Wins Booster Approval for Its COVID-19 Vaccine, But Won't Sell It This Season | 3 | Tokyo Brief | ||
| 16.09. | Shionogi's Eczema Cream Wins Japanese Approval for Children Under 12 | 4 | Tokyo Brief | ||
| 09.09. | StemRIM's Shionogi-Partnered Stroke Drug Misses Its Primary Endpoint While a Rare-Disease Trial Delivers | - | Tokyo Brief | ||
| 05.08. | Shionogi CEO says firm is pursuing acquisitions and mulling expanded U.S. production | 3 | Japan Times | ||
| 03.08. | Shionogi & Co. GAAP EPS of ¥114.78, revenue of ¥163.31B; reaffirms FY 2027 outlook | 6 | Seeking Alpha | ||
| 03.08. | Shionogi & Co., Ltd. Bottom Line Advances In Q1 | 485 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) announced a profit for its first quarter that Increased, from the same period last yearThe company's bottom line came in at JPY97.696 billion,... ► Artikel lesen | |
| 20.07. | Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth | 4 | Zacks | ||
| 15.06. | UBS stuft Shionogi-Aktie hoch: Günstige Bewertung und Pipeline als Kaufargumente | 10 | Investing.com Deutsch |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 9,753 | -1,64 % | Trulieve Cannabis Corp.: Trulieve Reports Third Quarter 2026 Results | Third quarter revenue of $230 million, with 64% gross marginCash flow from operations of $183 million and free cash flow of $120 million* in first nine months of 2026Received final DEA registrations... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 370,30 | +0,16 % | Dividendenbekanntmachungen (10.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGNC INVESTMENT CORP US00123Q1040 0,12 USD EUR AMBRA SA PLAMBRA00013 1,1 PLN EUR AMERICA MOVIL SAB DE CV MX01AM050019 0,27... ► Artikel lesen | |
| SHIONOGI | 17,175 | +1,12 % | Shionogi H1 Earnings Up 44%, Raises FY26 Outlook | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF), a Japanese drug manufacturing company, reported a 44 percent rise in profit for the first half of fiscal 2026 on higher revenues that grew 64.5... ► Artikel lesen | |
| KALA BIO | 0,170 | -0,47 % | KALA Bio Inc.: KALA BIO Announces Reverse Stock Split | Common Stock Will Begin Trading on a Split-Adjusted Basis on November 16, 2026Arlington, Massachusetts--(Newsfile Corp. - November 12, 2026) - KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the "Company")... ► Artikel lesen | |
| CHARLOTTES WEB | 0,132 | -8,97 % | Charlotte's Web Holdings, Inc. - 10-Q, Quarterly Report | ||
| MIRUM PHARMACEUTICALS | 85,78 | +1,30 % | Mirum Pharmaceuticals auf der Stifel Healthcare Conference: Breiteres Wachstum bei anhaltend hohem Investitionsbedarf | ||
| BEXIMCO PHARMACEUTICALS | 0,625 | 0,00 % | Beximco Pharma. - Results for the year ended 30 June 2026 | ||
| LUYE PHARMA | 0,190 | +1,06 % | LUYE PHARMA (02186): INTERIM REPORT 2026 | ||
| PERCHERON THERAPEUTICS | 0,001 | 0,00 % | PERCHERON THERAPEUTICS LIMITED: Updated Top 20 Option Holders Report | ||
| AYURCANN | 0,001 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.07.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 02.07.2026
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.07.2026
ISIN Name
CA05476A1012... ► Artikel lesen | |
| AVANT BRANDS | 0,346 | -3,35 % | Avant Brands, Inc.: Avant Brands Reports Q3 2026 Results Highlighted by Positive Net Income and 51% Growth in Recreational Revenue | Net income of $0.2 million, compared to a net loss of $1.9 million in Q3 2025Adjusted EBITDA¹ of $1.3 million, compared to $0.2 million in Q3 2025Flowr kilograms harvested increased 57.5%, from 807... ► Artikel lesen | |
| KALBE FARMA | 0,030 | +3,45 % | Dividendenbekanntmachungen (04.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-LIVING SMART CITY SERVICES CO LTD CNE100002RY5 0,0688 HKD 0,0075 EUR ADESSO SE DE000A0Z23Q5 - 0,78 EUR AGEAS SA/NV ADR US00844W2089 2... ► Artikel lesen | |
| EVEREST MEDICINES | 3,040 | -1,94 % | Everest Medicines Limited: Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform | HONG KONG, Oct 9, 2026 - (ACN Newswire) - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 38,000 | -1,55 % | Kobayashi Pharmaceutical Co., Ltd. Nine Months Income Climbs | ||
| SILO WELLNESS | 0,008 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.11.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 03.11.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.11.2026ISIN NameAU000000MFG4 BARRENJOEY... ► Artikel lesen |
SHIONOGI & CO LTD ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 8,700 Euro und damit 0,00 % im Plus. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHIONOGI & CO LTD ADR finden Sie auf Wallstreet Online.